BioMarin Pharmaceuticals BMRN VIMIZIM — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's vimizim — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's VIMIZIM — total revenues?
- BioMarin Pharmaceuticals (BMRN) reported VIMIZIM — total revenues of $210.2M in Q1 2026.
- How has BioMarin Pharmaceuticals's VIMIZIM — total revenues changed year-over-year?
- BioMarin Pharmaceuticals's VIMIZIM — total revenues increased by 11.6% year-over-year, from $188.35M to $210.2M.
- What is the long-term trend for BioMarin Pharmaceuticals's VIMIZIM — total revenues?
- Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's VIMIZIM — total revenues has grown at a 6.2% compound annual growth rate (CAGR), from $623.15M to $792.05M.
- What does VIMIZIM — total revenues mean?
- The total amount of money earned from selling a specific rare disease drug.
- How do you interpret VIMIZIM — total revenues?
- An increase indicates growing market adoption, successful patient retention, or expanded geographical reach for the therapy. A decrease may signal increased competition, loss of patent exclusivity, or shifts in reimbursement policies.
- How does VIMIZIM — total revenues compare across companies?
- Comparable to product-specific net sales or segment revenue reported by other specialty pharmaceutical and biotechnology firms.